PPARG and Parkinson disease: GTZ drugs stimulate the PPARγ, which, via the PPARγ coactivator 1‐α pathway, leads to increased mitochondrial biogenesis.15 This could partly compensate for the mitochondrial pathology that characterizes PD such as accumulation of somatic mitochondrial DNA (mtDNA) damage16 and respiratory deficiencies.17 It is possible, that GTZ drugs ameliorate these defects by increasing mtDNA synthesis and overall mitochondrial mass.